« Previous
Next »
Gastroenterology
Volume 133, Issue 5
, Pages
1414-1422
, November 2007
A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis
To access this article, please choose from the options below
Supported by the sponsor, PDL BioPharma, Fremont, CA.
The authors declare the following conflicts of interest: consultant, PDL BioPharma (S.P., G.V., M.R., D.H., W.S., S.H., S.T., L.M., U.M.); research support for clinical trial, PDL BioPharma (S.P., B.S., G.V., M.R., D.H., W.S., S.H., S.T., L.M., U.M.); speaker at continuing medical education symposia sponsored by PDL BioPharma (S.P., W.S., S.H., D.H.).
ClinicalTrials.gov identifier: NCT00032305.
PII: S0016-5085(07)01491-6
doi: 10.1053/j.gastro.2007.08.035
© 2007 AGA Institute. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Gastroenterology
Volume 133, Issue 5
, Pages
1414-1422
, November 2007

